C Harper-Wynne - Maidstone and Tunbridge Wells NHS Trust

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 39 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Implementation of Oncotype Dx to Guide Chemotherapy Sparing for Women with Postmenopausal N1-3, ER-positive, HER-2-negative Breast Cancer

L. Rajakumar, J. Glendenning, J. Hall,R. Burcombe,G. McCormick,G. Hegarty,C. Harper-Wynne, B. Brown, C. Moss, C. Thomas,R. Jyothirmayi, M. Osman, L. Nikiforidis

CLINICAL ONCOLOGYno. 4 (2024): E111-E111

引用0浏览0引用

Breast Cancers with a HER2/CEP17 Ratio of 2.0 or Greater and an Average HER2 Copy Number of Less Than 4.0 Per Cell: Frequency, Characteristics and Survival Outcomes in Those Receiving HER2-targeted Treatment

G. Patel, Y.-C. Lam, J. Brown,G. Donald,C. Harper-Wynne

Clinical Oncologyno. 6 (2023)

引用0浏览0引用

199P Advanced Breast Cancer Patient Involvement in the Evaluation of an Available Online Exercise Program for Use in a Future Clinical Trial

C. Harper-Wynne,J. L. Glendenning,G. Davison

Annals of oncology (2022): S219-S219

引用0浏览0引用

142P Bone mineral density (BMD) after three years of adjuvant zoledronic acid (ZA) in postmenopausal oestrogen receptor positive (ER+) early breast cancer (EBC): An observational single centre study

C. Harper-Wynne,R. Burcombe

Annals of Oncology（2021）

引用0浏览0引用

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

I Porter, E Theodoulou,I Holen,C Harper-Wynne,S Baron-Hay,C Wilson,J Brown

Journal of Bone Oncology（2021）

引用3浏览0WOS引用

A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program

C. Palmieri, A. Musson,C. Harper-Wynne,D. Wheatley, G. Bertelli,I. MacPherson, M. Nathan,M. Verrill, J. Eva, C. Doody, R. Chowdhury

ANNALS OF ONCOLOGY (2021): S464-S464

引用1浏览0引用

107P CDK4/6i adjustment & tumour response in the COVID-19 era

Z. Tippu,C. Ryan,C. Harper-Wynne

Annals of Oncology（2021）

引用0浏览0引用

Fulvestrant Plus Vistusertib Vs Fulvestrant Plus Everolimus Vs Fulvestrant Alone For Women With Hormone Receptor-Positive Metastatic Breast Cancer: The Manta Phase 2 Randomized Clinical Trial (Vol 5, Pg 1556, 2019)

P. Schmid,M. Zaiss,C. Harper-Wynne

JAMA ONCOLOGY（2021）

引用65浏览0引用

The Assessment of Bone Mineral Density (BMD) and Fracture Risk after 3 Years of Adjuvant Zoledronic Acid in Postmenopausal (ER+) Early Breast Cancer

G. Eslamian,C. Harper-Wynne

Clinical Oncology（2020）

引用0浏览0引用

Enhanced Axillary Assessment Using Contrast Enhanced Ultrasound (CEUS) Before Neo-Adjuvant Systemic Therapy (NACT) in Breast Cancer Patients Identifies Axillary Disease Missed by Conventional B-mode Ultrasound That May Be Clinically Relevant

K. Cox, N. Dineen,J. Weeks, D. Allen, D. Akolekar, R. Chalmers,R. Burcombe,C. Harper-Wynne,R. Jyothirmayi,C. Abson

European journal of cancer（2020）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn